The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05426018

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Suzhou Yabao Pharmaceutical R&D Co., Ltd. (from the registry)
Registry
  • NCT NCT05426018
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05426018. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-01 (anticipated); primary completion 2023-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
Intervention (Drug)
SY-009 capsules
Lead sponsor
Suzhou Yabao Pharmaceutical R&D Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05426018
Content hash
8b36e5c5aa2983de5f2a9f277bb6b251fdb0a06af10b03207ad10e22c3cfec00